From Discovery to Therapy: 10AM – 11AM

4drugs Shapiro Breakout Room | 10AM – 11AM This mini-symposia focuses on immunotherapy.

Introduction

Scott Snapper, MD, PhD, Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women’s Hospital

Anti-IL17: From Bench to Therapy

Vijay Kuchroo, DVM, PhD, Department of Neurology, Brigham and Women’s Hospital Simon Cooper, Novartis Dr. Cooper is the Global Program Medical Director for secukinumab, a recombinant high-affinity, fully human monoclonal anti-human antibody that selectively targets IL-17A and is being developed for the treatment of a number of diseases including psoriasis, rheumatoid arthritis and ankylosing spondylitis.

Low Dose IL-2: Successes in graft vs host disease

Jerome Ritz Dr. Ritz’s laboratory focuses on immune reconstitution after allogeneic hematopoietic stem cell transplantation (HSCT).  In patients with hematologic malignancies undergoing HSCT, engraftment of donor immune cells contributes to elimination of residual leukemia. However, the inability to establish immune tolerance to normal tissues in the recipient also causes graft versus host disease (GVHD).  Studies of immune reconstitution after allogeneic HSCT have identified mechanisms of GVHD and  have led to the development of novel clinical strategies to enhance and maintain immune tolerance after transplant.

Anti PD-1: Highlighting results in melanoma

Arlene Sharpe

Cadherin-11 and RA

Michael Brenner, MD Dr. Brenner’s laboratory identified gd T cells and their antigen receptor, the molecular chaperone calnexin, the integrin and mucosal homing molecule aE/b7 (CD103), the CD1 antigen presentation system for lipid antigens that activate T cells and NKT cells, and the role of cadherins in rheumatoid arthritis. Current research focuses on innate T cells and their role in host defense and immunoregulation.  Current research is also defining the role of fibroblasts in inflammation and tissue damage.

Session Co-Chairs

Kuchroo-HiResPic

Vijay Kuchroo, DVM, PhD Dr. Vijay Kuchroo is the Samuel L. Wasserstrom Professor of Neurology at Harvard Medical School, Senior Scientist at Brigham and Women’s Hospital, and Co-Director of the Center for Infection and Immunity, Brigham Research Institutes, Boston. Vijay Kuchroo is also an associate member of the Broad Institute and a participant in a Klarman Cell Observatory project that focuses on T cell differentiation. His major research interests include autoimmune diseases – particularly the role of co-stimulation – the genetic basis of experimental autoimmune encephalomyelitis and multiple sclerosis, and cell surface molecules and regulatory factors that contribute to susceptibility and resistance to autoimmune diseases. His laboratory has made several transgenic mice that serve as animal models for human multiple sclerosis.

 

 

CD2707D0-C8B2-4492-8240-82BAADAF0A40Scott Snapper, MD Dr. Snapper is a Gastroenterologist and Immunologist whose clinical and research focus is on the relationship between immune deficiencies and the development of Very Early Onset IBD. For the last decade his laboratory has investigated how the adaptive and innate arms of the immune system maintain health in the intestine. Employing studies in mice and humans, his laboratory has made numerous key discoveries of how a defective immune system, through altered immunoregulatory circuits, can contribute simultaneously to immunodeficiency and intestinal inflammation.